ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Prostate Cancer Metastatic Clinical Trial

Official title:

A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04916613
• Other study ID #: UC-GTG-2006
• Secondary ID: 2020-003663-26
• Status: Recruiting
• Phase: Phase 3
• Start date: April 19, 2022
• Est. completion date: September 2033

Study information

• Verified date: May 2023
• Source: UNICANCER
• Contact: Soazig N Ficher
• Phone: +33 (0) 1 85 34 31 13
• Email: s-nenan[@]unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase III, international, multicentre, randomised, double-blinded placebo controlled trial, evaluating the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors.

Description:

This is a Phase III, international, multicentre, randomised, double-blinded placebo controlled trial, evaluating the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors. The study plans to enroll 300 patients who will be randomized (1:1) to receive either: (i) Experimental arm: ADT + darolutamide 600 mg po bid, or (ii) Control arm: ADT + placebo po bid. Response to treatment will be assessed according to the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (Scher, 2016). Treatment will be continued until radiographic disease progression. Treatment may also be terminated at the initiative of either the patient or the investigator for any reason that would be beneficial to the patient, including: unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient request. Following treatment discontinuation patients will enter the follow-up period and will be monitored for up to 10 years with regards to survival status, subsequent antineoplastic treatments and the status of ongoing adverse events (AEs) and/or new investigational product related AEs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: September 2033
• Est. primary completion date: March 2028
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed a written informed consent form prior to any trial specific procedures.

2. Men with histologically or cytologically confirmed adenocarcinoma of the prostate.

3. Aged =18 years old at the time of signing informed consent.

4. De novo metastatic disease defined by clinical or radiological evidence of metastases.

Note: For patients with nodal metastases only, only patients with extra-pelvic enlarged lymph nodes (lymph nodes located above the iliac bifurcation) can be included if they have either:

• At least one extra-pelvic lymph node =2 cm

• At least one extra-pelvic lymph node =1 cm if the patients also have at least one pelvic lymph node =2 cm

5. Measurable disease or bone lesions that are evaluable according to PCWG3 criteria.

6. Ineligible for treatment with all of the following drugs: docetaxel, abiraterone, enzalutamide, apalutamide; AND meets at least one of the following frailty criteria:

1. Activities of daily living (ADL) assessment (excluding urinary incontinence question) score 3 or 4/5;

2. 4-Instrumental activities of daily living (4-IADL) assessment score 2 or 3/4;

3. A Grade 3 event on the Cumulative Illness Score Rating-Geriatrics (CISR-G) questionnaire;

4. Body mass index (BMI) =21 kg/m² and/or >10% weight loss in the last 6 months;

5. Timed up and go test (TUG) >14 sec.

7. Adequate bone marrow function: haemoglobin =80 g/L, white blood cells =3.0 x10?/L and platelets =80 x10?/L.

8. Adequate liver function: alanine aminotransferase (ALT) <2 x upper limit of normal (ULN) and bilirubin <1.5 x ULN, (or if bilirubin is between 1.5-2 x ULN, they must have a normal conjugated bilirubin). For patients with documented liver metastasis, ALT <5 x ULN is acceptable.

9. Adequate renal function: calculated creatinine clearance >30 ml/min (using the Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology Collaboration [CKD EPI) method).

10. For sexually active men, agreement to use adequate contraception for the duration of trial participation and up to 2 weeks after completing study treatment.

11. Affiliated to the social security system or in possession of equivalent private health insurance (according to local regulations for participation in clinical trials).

12. Willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion Criteria:

1. Three or more Grade 3, or any Grade 4 events on the CISR-G questionnaire.

2. Eastern Cooperative Oncology Group (ECOG) performance status score =3.

3. Hypertension not controlled by an anti-hypertensive treatment (systolic blood pressure [BP] =160 mmHg or diastolic BP =95 mmHg; 3 consecutive measures taken 5 minutes apart).

4. Acute toxicities of prior treatments and procedures not resolved to grade =1 or baseline before randomisation, with the exception of hot flushes and erectile dysfunction.

5. Previous systemic treatment for prostate cancer, except less than 12 weeks of ADT and/or an old-generation AR inhibitor.

6. Severe or uncontrolled concurrent disease, infection or co-morbidity.

7. Known hypersensitivity to the study treatment or any of its ingredients.

8. Major surgery within 28 days before randomisation.

9. Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV.

10. Prior malignancy =3 years before study enrolment. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any localized cancer for which treatment has been completed =6 months before randomisation and from which the subject has been disease-free, or for which the risk of relapse is less than 30%, as well as early stage chronic lymphocytic leukaemia that does not require any specific treatment.

11. Inability to swallow oral medications.

12. Gastrointestinal disorder or procedure that can be expected to interfere significantly with the absorption of study treatment.

13. Known to have active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease at screening.

14. Treatment with any investigational product within 28 days before randomisation.

15. Concurrent participation in another clinical trial involving an investigational product (patients enrolled in non-experimental trials with no modification of the standard of care can be included).

16. Individual deprived of liberty or placed under the authority of a tutor.

17. Significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule or any condition that, in the opinion of the investigator, would preclude participation in this trial.

Related Conditions & MeSH terms

• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Drug:
• Darolutamide 300 mg
600 mg po, b.i.d.
• Placebo
po, b.i.d.
• Androgen deprivation therapy
Use according to local standard of care

Locations

Country	Name	City	State
Belgium	Grand Hopital de Charleroi - site Notre Dame	Charleroi
Belgium	Groupe Jolimont - Hôpital De Jolimont	Haine-Saint-Paul
Belgium	CHU UCL NAMUR - Site STE. ELISABETH	Namur
Belgium	Clinique Saint Pierre	Ottignies
France	Institut Sainte Catherine	Avignon
France	Centre Hospitalier Cote basque	Bayonne
France	CHU Besançon - Hopital Jean Mijoz	Besançon
France	Centre Institut Bergonié	Bordeaux
France	Clinique Pasteur	Brest
France	Centre François Baclesse	Caen
France	Centre Hospitalier Métropole Savoie	Chambéry
France	Centre Jean Perrin	Clermont-Ferrand
France	APHP - Hôpital Henri Mondor	Créteil
France	Centre Georges François Leclerc	Dijon
France	CHU Grenoble	Grenoble
France	Centre CHV Vendée	La Roche-sur-Yon
France	CHU le MANS	Le Mans
France	Centre Oscar Lambret	Lille
France	Polyclinique de Limoges	Limoges
France	Groupe Hospitalier Bretagne Sud	Lorient
France	Centre Léon Bérard	Lyon
France	Institut Paoli-Calmettes	Marseille
France	Centre Azuréen de Cancérologie	Mougins
France	Centre Antoine Lacassagne	Nice
France	CHU Nîmes	Nîmes
France	Centre Groupe Hospitalier Diaconesses Croix Saint-Simon	Paris
France	Hôpital Européen Georges Pompidou	Paris
France	Hôpital Saint Louis	Paris
France	Hôpital Tenon	Paris
France	Institut Curie	Paris
France	Hospices Civils de Lyon -Lyon Sud	Pierre-Bénite
France	CHU de Poitiers - Pôle Régional de Cancérologie	Poitiers
France	CH Annecy Genevois	Pringy
France	CHIC Quimper	Quimper
France	Institut Jean Godinot	Reims
France	Centre Eugène Marquis	Rennes
France	Centre Hospitalier Rodez	Rodez
France	CHP Centre Saint Grégoire	Saint Grégoire
France	Hôpital Instruction des Armées - BEGIN	Saint Mandé
France	CHU Saint-Etienne	Saint-Étienne
France	Hôpital Privé de la Loire	Saint-Étienne
France	Clinique Sainte Anne - Strasbourg Oncologie Libérale	Strasbourg
France	Institut de cancérologie Strasbourg Europe	Strasbourg
France	Hôpital FOCH	Suresnes
France	Centre Hospitalier Intercommunal de Toulon-La Seyne - Hôpital Ste Musse	Toulon
France	Clinique Pasteur ONCORAD	Toulouse
France	IUCT Oncopole	Toulouse
France	CHRU de Tours -Hôpital Bretonneau	Tours
France	Institut de Cancérologie de Lorraine	Vandœuvre-lès-Nancy
France	Gustave Roussy Center	Villejuif
Ireland	Mater Misericordiae University Hospital	Dublin
Ireland	Mater Private Hospital	Dublin
Ireland	St Vincent's University Hospital	Dublin
Ireland	Tallaght university Hospital	Dublin
Spain	Institut Catala d'Oncologia, Badalona-Hospital Germans Trias i Pujol	Badalona
Spain	Hospital Clinic	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Vall d'Hebron Institute of Oncology. Vall d'Hebron University Hospital	Barcelona
Spain	Institut Català d'Oncologia de Girona	Girona
Spain	Centro Integral Oncologico HM Clara Campal	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Althaia, Xara Assistencial Universitaria Mansera	Manresa
Spain	Fundacion Instituto Valenciano De Oncologia	Valencia

Sponsors (2)

Lead Sponsor	Collaborator
UNICANCER	Bayer

Countries where clinical trial is conducted

Belgium,  France,  Ireland,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiographic progression-free survival	Time from randomisation to radiographic progression according to the Prostate Cancer Working Group 3 (PCWG3) criteria or death, whichever occurs first	From randomisation to radiographic progression or death, up to 18 months
Secondary	Castration-resistant prostate cancer-free survival	Time from randomisation to onset of castrate resistant prostate cancer (CRPC) according to PCWG3 criteria, or death, whichever occurs first	From randomisation to onset of CRPC or death, up to 18 months
Secondary	Clinical progression-free survival	Time from randomisation to first occurrence of any one of the following: (i) Cancer pain deterioration (2-point deterioration from baseline according to the Brief Pain Inventory - Short Form [BPI-SF] questionnaire; initiation of opioid therapy, or a =30% increase in opiate use) (ii) Any deterioration of physical function measured using the 4-IADL assessment tools (Lawton, 1969) (iii) A deterioration in ECOG performance status of at least 2 points from baseline (iv) Death from any cause.	From randomisation to clinical progression or death, up to 18 months
Secondary	Overall survival	Time from randomisation to the time of death from any cause	From randomization to death from any cause, up to 10 years.
Secondary	Frequency and severity of adverse events	The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders	From inclusion until 100 days after last dose of investigational product
Secondary	Time to worsening in prostate cancer-related urinary symptoms	Time from randomisation to first increase from baseline of greater or equal to 8 points in the urinary symptom scale/score (PRURI) measured using the prostate cancer module of the EORTC quality of life questionnaire (EORTC-QLQ-PR25).; This EORTC prostate cancer specific questionnaire is intended to supplement the QLQ-C30. The prostate cancer module is a 25-item questionnaire designed for use among patients with localized and metastatic prostate cancer. It includes subscales assessing urinary symptoms (9 items), bowel symptoms (4 items), treatment-related symptoms (6 items) and sexual functioning (6 items). Using a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), patients indicate the degree to which they have experienced symptoms.	On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year
Secondary	Time to next symptomatic skeletal event	Time from randomisation until first occurrence of one of the following: a symptomatic fracture, radiation or surgery to bone or a spinal cord compression	From randomisation to occurence of a skeletal event, up to 18 months
Secondary	Complete prostate specific antigen (PSA) response	Defined according to PCWG3 criteria as PSA = 0.2 ng/ml	At 6 months
Secondary	Prostate cancer-specific survival	Time from randomisation to the date of death due to prostate cancer (deaths due to other causes will be censored)	From randomization to death from prostate cancer, up to 10 years.
Secondary	Time to first subsequent systemic anti-cancer therapy (SACT)	Time from randomisation to the date of initiation of any SACT for CRPC, following initiation of the study treatment	From randomization up to 10 years.
Secondary	Second line radiographic progression-free survival	Time from the date of initiation of a second SACT for CRPC to radiographic progression or death, whichever occurs first.	From randomization up to 10 years.
Secondary	Second line overall survival	Time from the date of initiation of a second SACT for CRPC to death	From randomization up to 10 years.
Secondary	Progression-free survival after next line of treatment (PFS2)	Time from randomisation to second objective disease progression, or death from any cause, whichever first	From randomization up to 10 years.
Secondary	Geriatric status	Evaluated using the G-CODE (Paillaud, 2018), a core set of commonly used tools/items for geriatric assessment which has been validated for the collection of geriatric data in clinical cancer trials of older adults, enabling comparison across trials. The tools/items proposed in G-CODE are: (i) Social assessment: living alone or support requested to stay at home; (ii) Functional autonomy: Activities of Daily Living (ADL) questionnaire and short instrumental ADL questionnaire (4-IADL); (iii) Mobility: Timed Up and Go test; (iv) Nutrition: weight loss during the past 6 months and body mass index; (v) Cognition: Mini-Cog test; (vi) Mood: mini-Geriatric Depression Scale; (vii) Comorbidity: updated Charlson Comorbidity Index.	At baseline and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year
Secondary	Time to deterioration for EORTC QLQ-PR25 symptom subscales	Defined as the first decline in the HRQoL score from baseline equal to or greater than the minimally important difference (MID; a measure of clinical significance) defined as half the standard deviation of the baseline value for each subscale. The prostate cancer module QLQ-PR25 is a 25-item questionnaire designed for use among patients with localized and metastatic prostate cancer. It includes subscales assessing urinary symptoms (9 items), bowel symptoms (4 items), treatment-related symptoms (6 items) and sexual functioning (6 items). Using a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), patients indicate the degree to which they have experienced symptoms.	On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year
Secondary	Health related quality of life questionnaire EORTC-QLQ-C30	Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.; The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.; All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.	On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year
Secondary	Health related quality of life questionnaire EORTC-QLQ-PR25	This EORTC prostate cancer specific questionnaire is intended to supplement the QLQ-C30.; The prostate cancer module is a 25-item questionnaire designed for use among patients with localized and metastatic prostate cancer. It includes subscales assessing urinary symptoms (9 items), bowel symptoms (4 items), treatment-related symptoms (6 items) and sexual functioning (6 items). Using a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), patients indicate the degree to which they have experienced symptoms.	On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year
Secondary	Health related quality of life questionnaire Brief Pain Inventory - Short Form (BPI-SF)	The Brief Pain Inventory is a self reporting tool to assess the severity of pain and the impact of pain on daily functions in patients with chronically painful diseases or conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain. The Short Form of the questionnaire (BPI-SF) has been specifically developed for clinical trials.	On treatment day 1 and every 120 days during first years of treatment and every 180 days thereafter if treatment is continued for more than 1 year